Repeated administration of cytosine-phosphorothiolated guanine- containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity

Journal of Immunology

Volumn 165, Issue 1, 2000, Pages 539-547

  Davila, Eduardo ^a   Celis, Esteban ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034235701     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.1.539     Document Type: Article

References (45)

1. Mayordomo, J. I., T. Zorina, W. J. Storkus, C. Celluzzi, L. Falo, W. M. Kast, S. T. Ildstad, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat. Med. 1:1297.
2. Gilboa, E. 1996. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol. 23:101.
3. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
4. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996 Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769. .
5. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
6. Jaffee, E. M., R. Abrams, J. Cameron, R. Donehower, M. Duerr, J. Gossett, T. F. Greten, L. Grochow, R. Hruban, S. Kern, et al. 1998. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum. Gene Ther. 9:1951.
7. Boon, T., and P. v. d. Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
8. Urban, J. L., and H. Schreiber. 1992. Tumor antigens. Annu. Rev. Immunol. 10:617.
9. Boon, T., J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
10. Kawashima, I., V. Tsai, S. Southwood, K. Takesako, A. Sette, and E. Celis. 1999. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59:431.
11. Kawashima, I., S. Hudson, V. Tsai, S. Southwood, K. Takesako, E. Appella, A. Sette, and E. Celis. 1998. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59:1.
12. Celis, E., V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey. A. Sette, and H. M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105.
13. Nukaya, I., M. Yasumoto, T. Iwasaki, M. Ideno, A. Sette, E. Celis, K. Takesako, and I. Kato. 1999. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int. J. Cancer 80:92.
14. Toes, R. E., E. I. van der Voort, S. P. Schoenberger, J. W. Drijfliout, L. van Bloois, G. Storm, W. M. Kast, R. Offringa, and C. J. Melief. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160:4449.
15. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991.
16. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1249.
17. Krieg, A. M. 1999. CpG DNA: a novel immunomodulator. Trends Microbiol. 7:64.
18. Wagner, H. 1999. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73:329.
19. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
20. Alexander, J., J. Sidney, S. Southwood, J. Ruppert, C. Oseroff, A. Maewal, K. Snoke, H. M. Serra, R. T. Kubo, A. Seite, et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751.
21. Davis, H. L., R. Weeratna, T. J. Waldschmidt, L. Tygrett, J. Schorr, A. M. Krieg, and R. Weeranta. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in 1999, J. Immunol. 162:3103]. J. Immunol. 160:870.
22. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777.
23. Faas, S. J., J. L. Rothstein, B. L. Kreider, G, Rovera, and B. B. Knowles. 1993. Phenotypically diverse mouse thymic stromal cell lines which induce proliferation and differentiation of hematopoietic cells. Eur. J. Immunol. 23:1201.
24. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91:3916.
25. Kraal, G., M. Breel, M. Janse, and G. Bruin. 1986. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J. Exp. Med. 163:981.
26. Kalbfleisch, J. D., and R. L. Prentice. 1980. The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York.
27. Mylin, L. M., R. H. Bonneau, J. D. Lippolis, and S. S. Tevethia. 1995. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69:6665.
28. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:2045.
29. Hartmann, G., G. J. Weiner, and A. M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305.
30. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.
31. Rotzschke, O., K. Falk, S. Stevanovic, G. Jung, P. Walden, and H. G. Rammensee, 1991. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21:2891.
32. Rock, K. L., S. Gamble, and L. Rothstein. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918.
33. Mowat, A. M., A. M. Donachie, G. Reid, and O. Jarrett. 1991. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 72:317.
34. Sparwasser, T., L. Hultner, E. S. Koch, A. Luz, G. B. Lipford, and H. Wagner. 1999. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162:2368.
35. Bendigs, S., U. Salzer, G. B. Lipford, H. Wagner, and K. Heeg. 1999. CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur. J. Immunol. 29:1209.
36. Feltkamp, M. C., H. L. Smits, M. P. Vierbootn, R. P. Minnaar, J. B. M. De, J. W. Drijfhout, S. J. Ter, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J Immunol. 23: 2242.
37. Khoury, S. J., L. Gallon, W. Chen. K. Betres, M. E. Russell, W. W. Hancock, C. B. Carpenter, M. H. Sayegh, and H. L. Weiner. 1995. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J. Exp. Med. 182:357.
38. Seite, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
39. Alving, C. R. 1991. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 140:1.
40. Lipford, G. B., M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg. 1997. CpG-containing synthetic oligonucleolides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:2340.
41. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
42. Mackall, C. L., F. T. Hakim, and R. E. Gress. 1997. Restoration of T-cell homeostasis after T-cell depletion. Semin. Immunol. 9:339.
43. Jager, E., M. Ringhoffer, M. Altmannsberger, M. Arand, J. Karbach, D. Jager, F. Oesch, and A. Knuth. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71:142.
44. Ferrone, S., and F. M. Marincola. 1995. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16:487.
45. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.